Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems
Trial details
- Registry ID
- NCT07616206
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as TTP399
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) SystemsNCT07616206 | vTv Therapeutics | Phase 2 | Recruiting | 2027-06Estimated |
| Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 DiabetesNCT06334133 | vTv Therapeutics | Phase 3 | Active not recruiting | 2027-04Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |